Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …

Since the detection of cell‐free DNA (cfDNA) in human plasma in 1948, it has been
investigated as a non‐invasive screening tool for many diseases, especially solid tumours …

Precision oncology is predicated upon the ability to detect specific actionable genomic
alterations and to monitor their adaptive evolution during treatment to counter resistance …

Tissue biopsy is the standard diagnostic procedure for cancers and also provides a material
for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy …

Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant
organs. At primary diagnosis, prognostic markers are used to assess whether the transition …

It has been known for decades that it is possible to detect small amounts of extracellular
nucleic acids in plasma and serum of healthy and diseased human beings. The unequivocal …

Circulating cell-free RNA in the blood provides a potential window into the health,
phenotype, and developmental programs of a variety of human organs. We used high …

Although it is evident that DNA circulates freely in blood plasma both in disease and in
health, the source of this DNA remains enigmatic. It can be presumed that circulating DNA in …

It has been proposed that cell-free nucleic acids in the plasma participate in tumorigenesis
and the development of metastases via transfection-like uptake of such nucleic acids by …

As a kind of nanometric lipidic vesicles, exosomes have been presumed to play a leading
role in the regulation of tumor microenvironment through exosomes-mediated transfer of …